Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Updates on the ELIANA trial for acute lymphocytic leukaemia in young patients

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.12.18
Views: 178
Rating:

Dr Stephan Grupp - Children's Hospital of Philadelphia, Philadelphia, USA

Dr Stephan Grupp talks to ecancer at ASH 2018 about the latest analysis of the ELIANA trial.

He describes how tisagenlecleucel continues to show durable remissions in paediatric and young patients with relapsed or treatment-resistant acute lymphocytic leukaemia.

Dr Grupp says that the take home message is that there are patients that are going to have long term disease control just with the CAR T therapy.

Watch his press conference here.

Read more about this work here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation